Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a strong-buy rating in a research note issued to investors on Tuesday morning. They currently have $7.75 target price on the biotechnology company’s stock.

According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “

A number of other analysts have also weighed in on the stock. HC Wainwright reaffirmed a buy rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, August 13th. They noted that the move was a valuation call. BidaskClub raised shares of BioCryst Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, August 10th. Jefferies Financial Group reaffirmed a buy rating and issued a $8.50 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 9th. ValuEngine raised shares of BioCryst Pharmaceuticals from a hold rating to a buy rating in a research note on Wednesday, August 8th. Finally, Royal Bank of Canada reaffirmed a buy rating and issued a $9.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 7th. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $9.89.

Shares of BCRX opened at $7.01 on Tuesday. The firm has a market cap of $834.59 million, a PE ratio of -8.99 and a beta of 1.64. BioCryst Pharmaceuticals has a 12-month low of $4.12 and a 12-month high of $8.13. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 0.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.05. The firm had revenue of $12.49 million during the quarter, compared to analyst estimates of $3.80 million. BioCryst Pharmaceuticals had a negative net margin of 270.95% and a negative return on equity of 107.85%. Analysts predict that BioCryst Pharmaceuticals will post -0.86 EPS for the current year.

In other BioCryst Pharmaceuticals news, CMO William P. Sheridan sold 62,500 shares of the stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $7.03, for a total transaction of $439,375.00. Following the completion of the sale, the chief marketing officer now directly owns 85,713 shares of the company’s stock, valued at $602,562.39. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Thomas R. Staab II sold 9,850 shares of the stock in a transaction dated Wednesday, October 3rd. The shares were sold at an average price of $7.24, for a total transaction of $71,314.00. Following the sale, the insider now directly owns 140,633 shares of the company’s stock, valued at $1,018,182.92. The disclosure for this sale can be found here. 5.21% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the business. Paloma Partners Management Co purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $174,000. Spark Investment Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the second quarter valued at about $344,000. Wells Fargo & Company MN lifted its position in shares of BioCryst Pharmaceuticals by 29.3% during the first quarter. Wells Fargo & Company MN now owns 68,052 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 15,403 shares during the last quarter. State of Wisconsin Investment Board lifted its position in shares of BioCryst Pharmaceuticals by 79.1% during the second quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 44,300 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of BioCryst Pharmaceuticals by 114.2% during the second quarter. Bank of America Corp DE now owns 116,231 shares of the biotechnology company’s stock valued at $666,000 after buying an additional 61,960 shares during the last quarter. 80.23% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Featured Article: Relative Strength Index

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.